Cargando…

Genetic heterogeneity of actionable genes between primary and metastatic tumor in lung adenocarcinoma

BACKGROUND: Biopsy for lung cancer diagnosis is usually done at a single site. But it is unclear that genetic information at one biopsy site represents that of other lesions and is sufficient for therapeutic decision making. METHODS: Non-synonymous mutations and insertions/deletions of 16 genes cont...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Eun Young, Cho, Eun Na, Park, Heae Surng, Kim, Arum, Hong, Ji Young, Lim, Seri, Youn, Jong Pil, Hwang, Seung Yong, Chang, Yoon Soo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4717557/
https://www.ncbi.nlm.nih.gov/pubmed/26782967
http://dx.doi.org/10.1186/s12885-016-2049-z
_version_ 1782410672411246592
author Kim, Eun Young
Cho, Eun Na
Park, Heae Surng
Kim, Arum
Hong, Ji Young
Lim, Seri
Youn, Jong Pil
Hwang, Seung Yong
Chang, Yoon Soo
author_facet Kim, Eun Young
Cho, Eun Na
Park, Heae Surng
Kim, Arum
Hong, Ji Young
Lim, Seri
Youn, Jong Pil
Hwang, Seung Yong
Chang, Yoon Soo
author_sort Kim, Eun Young
collection PubMed
description BACKGROUND: Biopsy for lung cancer diagnosis is usually done at a single site. But it is unclear that genetic information at one biopsy site represents that of other lesions and is sufficient for therapeutic decision making. METHODS: Non-synonymous mutations and insertions/deletions of 16 genes containing actionable mutations, and intron 2 deletion polymorphism of Bcl2-like11 were analyzed in 41 primary tumor and metastatic lymph node (L/N) matched, pStage IIA ~ IIIA non-small cell lung cancer (NSCLC) samples using a next generation sequencing based technique. RESULTS: A total of 249 mutations, including 213 non-synonymous mutations, 32 deletions, and four insertions were discovered. There was a higher chance of discovering non-synonymous mutations in the primary tumors than in the metastatic L/N (138 (64.8%) vs. 75 (35.2%)). In the primary tumors, 106 G > A:C > T transitions (76.8%) of 138 non-synonymous mutations were detected, whereas in the metastatic L/N, 44 (58.7%) of 75 were discovered. A total 24 (11.3%) out of 213 non-synonymous mutations were developed in the context of APOBEC signature. Of those, 21 (87.5%) was detected in the primary tumors and 4 (16.7%) was detected in the metastatic L/N. When the mutation profiles between primary tumor and metastatic L/N were compared, 13 (31.7%) of 41 cases showed discrepant mutation profile. There were no statistically significant differences in disease free survival and overall survival between groups showing identical mutation profiles and those with discrepancy between primary and metastatic L/N. CONCLUSIONS: Genetic heterogeneity between the primary and L/N metastatic lesions is not infrequent finding to consider when interpreting genomic data based on the result of one site inspection. A large prospective study may be needed to evaluate the impact of genetic heterogeneity on the clinical outcomes of NSCLC patients. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12885-016-2049-z) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4717557
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-47175572016-01-20 Genetic heterogeneity of actionable genes between primary and metastatic tumor in lung adenocarcinoma Kim, Eun Young Cho, Eun Na Park, Heae Surng Kim, Arum Hong, Ji Young Lim, Seri Youn, Jong Pil Hwang, Seung Yong Chang, Yoon Soo BMC Cancer Research Article BACKGROUND: Biopsy for lung cancer diagnosis is usually done at a single site. But it is unclear that genetic information at one biopsy site represents that of other lesions and is sufficient for therapeutic decision making. METHODS: Non-synonymous mutations and insertions/deletions of 16 genes containing actionable mutations, and intron 2 deletion polymorphism of Bcl2-like11 were analyzed in 41 primary tumor and metastatic lymph node (L/N) matched, pStage IIA ~ IIIA non-small cell lung cancer (NSCLC) samples using a next generation sequencing based technique. RESULTS: A total of 249 mutations, including 213 non-synonymous mutations, 32 deletions, and four insertions were discovered. There was a higher chance of discovering non-synonymous mutations in the primary tumors than in the metastatic L/N (138 (64.8%) vs. 75 (35.2%)). In the primary tumors, 106 G > A:C > T transitions (76.8%) of 138 non-synonymous mutations were detected, whereas in the metastatic L/N, 44 (58.7%) of 75 were discovered. A total 24 (11.3%) out of 213 non-synonymous mutations were developed in the context of APOBEC signature. Of those, 21 (87.5%) was detected in the primary tumors and 4 (16.7%) was detected in the metastatic L/N. When the mutation profiles between primary tumor and metastatic L/N were compared, 13 (31.7%) of 41 cases showed discrepant mutation profile. There were no statistically significant differences in disease free survival and overall survival between groups showing identical mutation profiles and those with discrepancy between primary and metastatic L/N. CONCLUSIONS: Genetic heterogeneity between the primary and L/N metastatic lesions is not infrequent finding to consider when interpreting genomic data based on the result of one site inspection. A large prospective study may be needed to evaluate the impact of genetic heterogeneity on the clinical outcomes of NSCLC patients. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12885-016-2049-z) contains supplementary material, which is available to authorized users. BioMed Central 2016-01-18 /pmc/articles/PMC4717557/ /pubmed/26782967 http://dx.doi.org/10.1186/s12885-016-2049-z Text en © Kim et al. 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Kim, Eun Young
Cho, Eun Na
Park, Heae Surng
Kim, Arum
Hong, Ji Young
Lim, Seri
Youn, Jong Pil
Hwang, Seung Yong
Chang, Yoon Soo
Genetic heterogeneity of actionable genes between primary and metastatic tumor in lung adenocarcinoma
title Genetic heterogeneity of actionable genes between primary and metastatic tumor in lung adenocarcinoma
title_full Genetic heterogeneity of actionable genes between primary and metastatic tumor in lung adenocarcinoma
title_fullStr Genetic heterogeneity of actionable genes between primary and metastatic tumor in lung adenocarcinoma
title_full_unstemmed Genetic heterogeneity of actionable genes between primary and metastatic tumor in lung adenocarcinoma
title_short Genetic heterogeneity of actionable genes between primary and metastatic tumor in lung adenocarcinoma
title_sort genetic heterogeneity of actionable genes between primary and metastatic tumor in lung adenocarcinoma
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4717557/
https://www.ncbi.nlm.nih.gov/pubmed/26782967
http://dx.doi.org/10.1186/s12885-016-2049-z
work_keys_str_mv AT kimeunyoung geneticheterogeneityofactionablegenesbetweenprimaryandmetastatictumorinlungadenocarcinoma
AT choeunna geneticheterogeneityofactionablegenesbetweenprimaryandmetastatictumorinlungadenocarcinoma
AT parkheaesurng geneticheterogeneityofactionablegenesbetweenprimaryandmetastatictumorinlungadenocarcinoma
AT kimarum geneticheterogeneityofactionablegenesbetweenprimaryandmetastatictumorinlungadenocarcinoma
AT hongjiyoung geneticheterogeneityofactionablegenesbetweenprimaryandmetastatictumorinlungadenocarcinoma
AT limseri geneticheterogeneityofactionablegenesbetweenprimaryandmetastatictumorinlungadenocarcinoma
AT younjongpil geneticheterogeneityofactionablegenesbetweenprimaryandmetastatictumorinlungadenocarcinoma
AT hwangseungyong geneticheterogeneityofactionablegenesbetweenprimaryandmetastatictumorinlungadenocarcinoma
AT changyoonsoo geneticheterogeneityofactionablegenesbetweenprimaryandmetastatictumorinlungadenocarcinoma